ArticleEuropean heart journal. Case reports2026
Mitral valve posteromedial papillary muscle head rupture presenting after liposomal doxorubicin chemotherapy for metastatic lung liposarcoma: a case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Doxorubicin-induced cardiotoxicity classically manifests as dose-dependent left ventricular systolic dysfunction. Herein, we describe an unusual case of acute mitral papillary muscle rupture following cumulative anthracycline therapy, presenting despite a preserved ejection fraction. Case summary: A 78-year-old woman with metastatic liposarcoma and multiple cardiovascular risk factors developed acute dyspnoea 1 week after completing liposomal doxorubicin (cumulative absolute dose 534 mg). She previously received 5-fraction stereotactic body radiation therapy to the lower lung lobes in September 2024 (9 months prior), targeting fields in close geographic proximity to the diaphragmatic and inferior heart walls. Surveillance echocardiograms from 2022 to 2025 showed a preserved left ventricular ejection fraction (65%-75%). At presentation, cardiac biomarkers showed a normal brain natriuretic peptide and flat, minimally elevated troponins. Transoesophageal echocardiography confirmed an acute rupture of the posteromedial papillary muscle head and associated chordae causing severe (4+) mitral regurgitation. Open surgical intervention was deferred due to advanced malignancy and goals of care. Her acute heart failure was optimized medically with intravenous loop diuretics, low-dose lisinopril for afterload reduction, and metoprolol succinate, while home amlodipine and hydrochlorothiazide were discontinued. She stabilized and is undergoing evaluation for transcatheter edge-to-edge repair. Discussion: While a direct causal link is unproven, this case highlights a rare structural complication. We present this 'two-hit' model as a hypothesis-generating observation, suggesting that chemotherapy-induced structural changes might compound underlying ischaemic or radiation-induced vulnerabilities. As such, advanced imaging modalities may offer value in future efforts to implement risk-adapted surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.